Last reviewed · How we verify

Wainua — Competitive Intelligence Brief

Wainua (EPLONTERSEN) competitive landscape: 0 comparators, recent regulatory actions, upcoming PDUFA, patent timeline. Class: Transthyretin-directed RNA Interaction [EPC]. Area: Neuroscience.

marketed Transthyretin-directed RNA Interaction [EPC] Neuroscience Oligonucleotide Live · refreshed every 30 min

Target snapshot

Wainua (EPLONTERSEN) — Astrazeneca Ab. Wainua works by binding to the transthyretin RNA to prevent the production of the transthyretin protein.

Comparator set

Auto-detected by same drug class / molecular target / therapeutic area, ranked by phase + recency. Override with ?vs=slug1,slug2,….

DrugGenericSponsorPhaseClassTargetApproval / PDUFA
Wainua TARGET EPLONTERSEN Astrazeneca Ab marketed Transthyretin-directed RNA Interaction [EPC] 2025-01-01

Recent regulatory actions (last 90 days)

No regulatory actions in the last 90 days for this set.

Upcoming PDUFA dates (next 180 days)

No PDUFA dates in the next 180 days for this set.

Patent timeline (forward window)

No upcoming patent expiries for this set.

Sponsor landscape (Transthyretin-directed RNA Interaction [EPC] class)

  1. Astrazeneca Ab · 1 drug in this class

Subscribe to ongoing alerts

Push every new event for this competitive set into your RSS reader, IFTTT/Zapier workflow, or email digest:

Cite this brief

Drug Landscape (2026). Wainua — Competitive Intelligence Brief. https://druglandscape.com/ci/eplontersen. Accessed 2026-05-14.

Build your own brief

Pick any drug + add comparators: